Carias C., Walters M.S., Wefula E., Date K.A., Swerdlow D.L., Vijayaraghavan M., Mintz E.
Office of Science and Integrated Programs, Centers for Disease Control and Prevention, Atlanta, GA, United States; IHRC Inc, Atlanta, GA, United States; Epidemic Intelligence Service, Scientific Education and Professional Development Program Office, Centers for Disease Control and Prevention, Atlanta, GA, United States; Division of Foodborne, Waterborne and Environmental Diseases, Centers for Disease Control and Prevention, Atlanta, GA, United States; Kilembe Mines Hospital, Kasese, Uganda; Global Immunization Division, Centers for Disease Control and Prevention, Atlanta, GA, United States
Carias, C., Office of Science and Integrated Programs, Centers for Disease Control and Prevention, Atlanta, GA, United States, IHRC Inc, Atlanta, GA, United States; Walters, M.S., Epidemic Intelligence Service, Scientific Education and Professional Development Program Office, Centers for Disease Control and Prevention, Atlanta, GA, United States, Division of Foodborne, Waterborne and Environmental Diseases, Centers for Disease Control and Prevention, Atlanta, GA, United States; Wefula, E., Kilembe Mines Hospital, Kasese, Uganda; Date, K.A., Global Immunization Division, Centers for Disease Control and Prevention, Atlanta, GA, United States; Swerdlow, D.L., Office of Science and Integrated Programs, Centers for Disease Control and Prevention, Atlanta, GA, United States; Vijayaraghavan, M., Global Immunization Division, Centers for Disease Control and Prevention, Atlanta, GA, United States; Mintz, E., Division of Foodborne, Waterborne and Environmental Diseases, Centers for Disease Control and Prevention, Atlanta, GA, United States
Background: Vaccination has been increasingly promoted to help control epidemic and endemic typhoid fever in high-incidence areas. Despite growing recognition that typhoid incidence in some areas of sub-Saharan Africa is similar to high-incidence areas of Asia, no large-scale typhoid vaccination campaigns have been conducted there. We performed an economic evaluation of a hypothetical one-time, fixed-post typhoid vaccination campaign in Kasese, a rural district in Uganda where a large, multi-year outbreak of typhoid fever has been reported. Methods: We used medical cost and epidemiological data retrieved on-site and campaign costs from previous fixed-post vaccination campaigns in Kasese to account for costs from a public sector health care delivery perspective. We calculated program costs and averted disability-adjusted life years (DALYs) and medical costs as a result of vaccination, to calculate the cost of the intervention per DALY and case averted. Results: Over the 3 years of projected vaccine efficacy, a one-time vaccination campaign was estimated to avert 1768 (90%CI: 684-4431) typhoid fever cases per year and a total of 3868 (90%CI: 1353-9807) DALYs over the duration of the immunity conferred by the vaccine. The cost of the intervention per DALY averted was US$ 484 (90%CI: 18-1292) and per case averted US$ 341 (90%CI: 13-883). Conclusion: We estimated the vaccination campaign in this setting to be highly cost-effective, according to WHO's cost-effective guidelines. Results may be applicable to other African settings with similar high disease incidence estimates. © 2015 Elsevier Ltd.